David Kaslow, MD
PATH, Seattle, Washington, USA

David C. Kaslow, MD, is vice president PATH Essential Medicines, supporting PATH’s Drug Innovation and Access Initiative and PATH’s Center for Vaccine Innovation and Access (CVIA). As CVIA Head, David leads PATH’s work to advance immunization equity and vaccination coverage to reduce vaccine-preventable diseases through increasing and improving affordability, availability, acceptability, and sustainability of essential existing and new vaccines for routine immunization and pandemic/epidemic preparedness and response, particularly for those living in the lowest resources. His 35+ years of experience in product development and introduction include the US government (NIH), biotech (Vical), multi-national pharma (Merck Research Laboratories), and non-profit (PATH) sectors. David served in the US Public Health Service at NIAID, and serves on a number of advisory committees, including WHO Product Development of Vaccines Advisory Committee (PDVAC). David received a B.S. in biochemistry from University of California, Davis, and a M.D. from University of California, San Francisco.